Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombosis and ischemia: experimental data].

A Uzan1

  • 1Laboratoire Aventis-Pharma, 13, Quai Jules Guesde, 94403 Vitry-sur-Seine.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The salt content of food: a public health problem].

Annales pharmaceutiques francaises·2009
Same author

Combination of enoxaparin and fibroblast growth factor-1 increases myocardial blood flow and capillary density after myocardial infarction in rabbits.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes·2005
Same author

[Pharmacology, an innovative factor in therapeutic research].

Annales pharmaceutiques francaises·2005
Same author

[Introduction. Epidemiology].

Annales pharmaceutiques francaises·2004
Same author

[Protective effect of appendectomy on the development of ulcerative colitis. A case-control study].

Gastroenterologie clinique et biologique·2001
Same author

Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.

Stroke·2001

Enoxaparine effectively reduces coronary thrombus formation and myocardial infarction size in animal models. It also demonstrates anti-inflammatory effects, unlike standard heparin or aspirin, highlighting its potential in treating thrombosis-ischaemia-reperfusion injury.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Inflammation Research

Context:

  • Arterial thrombosis and ischaemia are frequently associated with atherosclerotic lesions, involving inflammation, plaque rupture, and platelet activation.
  • Reperfusion, while restoring blood flow, can paradoxically cause cytotoxicity due to necrotising factor release.
  • Animal models, including canine coronary occlusion and rat cerebral ischaemia, are crucial for studying thrombosis and ischaemia-reperfusion injury.

Purpose:

  • To evaluate the efficacy of Enoxaparine in preventing and treating arterial thrombosis and myocardial ischaemia in experimental models.
  • To compare the effects of Enoxaparine with standard heparin and aspirin in the context of thrombosis and ischaemia-reperfusion.
  • To investigate the anti-inflammatory mechanisms of Enoxaparine, specifically its effects on neutrophil and platelet accumulation.

Related Experiment Videos

Summary:

  • Enoxaparine significantly reduced coronary thrombus formation and potentiated tissue plasminogen activator (t-PA) efficacy in canine models.
  • In myocardial ischaemia models, Enoxaparine decreased infarct size and neutrophil/platelet accumulation, suggesting an anti-inflammatory action.
  • Standard heparin and aspirin showed limited or no efficacy under similar experimental conditions, underscoring Enoxaparine's distinct therapeutic profile.

Impact:

  • Enoxaparine demonstrates a dual anti-thrombotic and anti-ischaemic effect, offering a potential therapeutic strategy for complex cardiovascular events.
  • The findings support Enoxaparine's role in mitigating damage associated with the thrombosis-ischaemia-reperfusion triad.
  • This research highlights the importance of considering anti-inflammatory properties in anticoagulant therapies for cardiovascular diseases.